Skip to Main Content
DownloadHi-Res Photo

Nancy J. Brown, MD

Jean and David W. Wallace Dean of the Yale School of Medicine and C.N.H. Long Professor of Internal Medicine

Contact Information

Nancy J. Brown, MD

Research Summary

Dr. Brown's research has focused on the renin-angiotensin-aldosterone system, leading to discoveries on how that system affects glucose homeostasis, as well as fibrinolysis; the cardiovascular and renal effects of ACE inhibitors and other drugs used to control blood pressure; and the mechanisms of angioedema.

Extensive Research Description

  1. Role of the renin-angiotensin-aldosterone system in modulating oxidative stress, inflammation and fibrinolysis. The renin-angiotensin-aldosterone system (RAAS) is one of the major blood pressure regulating systems in the body. The small peptide angiotensin II, Ang II, raises blood pressure by constricting blood vessels and increasing salt retention, in part by stimulating synthesis of the mineralocorticoid aldosterone. We now understand that the RAAS has other detrimental effects on the blood vessels, heart and kidney. Both Ang II and aldosterone cause inflammation and fibrosis and promote clotting. Studies in our laboratory have examined the mechanisms of these effects.
  2. Role of the renin-angiotensin-aldosterone system in regulating glucose homeostasis. Sixty per cent of Americans are obese and both the activity of the RAAS and inflammation are increased in obesity. Obese individuals are at increased risk for the development of diabetes and hypertension, but drugs that interrupt the RAAS seem to decrease this risk. Studies in our laboratory have helped elucidate the mechanism for this effect in order to devise better strategies to prevent diabetes.
  3. Cardiovascular effects of the kallikrein-kinin system. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are the two major classes of drugs currently used to interrupt the renin-angiotensin-aldosterone system. ACE inhibitors decrease the formation of Ang II, whereas ARBs block the effect of Ang II at its major receptor. In addition, ACE inhibitors prevent the breakdown of and promote the actions of bradykinin, a peptide in the body that lowers blood pressure. Bradykinin has other beneficial effects, like increasing tissue-type plasminogen activator from the endothelium. Bradykinin can also have detrimental effects, promoting inflammation. The net beneficial or detrimental effect of bradykinin may depend on the health of the blood vessels.
  4. Role of arachidonic acid monooxygenases and epoxygenases in the regulation of blood pressure and cardiovascular risk. Bradykinin exerts its blood pressure lowering effects, in part, through effects on cytochrome P450 (CYP450) epoxygenases that form eicosatetraenoic acids (EETs) from arachidonic acid. EETs relax blood vessels. EETs formed in the kidney also stimulate salt excretion. Animal studies suggest that, in the kidney, EET formation is regulated in part by 20-hydroxyeicosatetraenoic acid 20-HETE, the product of CYP4A11. Research in our laboratory found that a loss-of-function variant of the gene encoding CYP4A11 is associated with high blood pressure and progression of renal disease. This has helped refine our understanding of how these systems regulate blood pressure in humans and how they interact with the RAAS.
  5. Contribution of peptidases to angiotensin-converting enzyme (ACE) inhibitor-associated angioedema. Despite the many beneficial effects of ACE inhibitors, this class of medications can cause swelling of the lips, tongue, or face, a side effect called angioedema. Likely, this side effect results from decreased breakdown of bradykinin and another peptide called substance P. We have determined groups of patients who are at increased risk for angioedema. Studies in our laboratory have identified one pathway involved in angioedema, allowing us to better predict risk and prevent the side effect.
  6. Pharmacogenetics of the renin-angiotensin-aldosterone and kallikrein-kinin sytems. Genetic factors modulate all of the processes described above. One goal of our laboratory has been to identify these factors in order to better predict individual responses to drugs such as ACE inhibitors, ARBs, aldosterone receptor blockers and renin inhibitors.

Coauthors

Research Interests

Angioedema; Angiotensin-Converting Enzyme Inhibitors; Atrial Fibrillation; Fibrinolysis; Hypertension; Inflammation; Kallikreins; Renin-Angiotensin System

Selected Publications

  • Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal.Mashayekhi M, Wilson JR, Jafarian Kerman S, Nian H, Yu C, Shuey MM, Luther JM, Brown NJ. Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal. Diabetes, Obesity & Metabolism 2021, 23: 281-286. PMID: 33001556, PMCID: PMC8142152, DOI: 10.1111/dom.14216.
  • Connecting Generations of Scientists in the Council on Hypertension Through Harriet Dustan.Watts SW, Alexander BT, Baylis C, Brown NJ, Cassis LA, Denton KM, Joe B, Lerman LO, Oparil S, Reckelhoff JF, Sandberg K, Touyz RM. Connecting Generations of Scientists in the Council on Hypertension Through Harriet Dustan. Hypertension 2021, 77: 296-307. PMID: 33390045, PMCID: PMC7856247, DOI: 10.1161/HYPERTENSIONAHA.120.16623.
  • Treatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids.Luther JM, Wei DS, Ghoshal K, Peng D, Adler GK, Turcu AF, Nian H, Yu C, Solorzano CC, Pozzi A, Brown NJ. Treatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids. Hypertension 2021, 77: 1323-1331. PMID: 33583202, PMCID: PMC8320355, DOI: 10.1161/HYPERTENSIONAHA.120.14808.
  • Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan.Dillon EM, Wei SD, Gupta DK, Nian H, Rodibaugh BS, Bachmann KN, Naftilan AJ, Stevenson LW, Brown NJ. Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan. Journal Of Cardiac Failure 2021, 27: 1231-1239. PMID: 34133968, PMCID: PMC8578199, DOI: 10.1016/j.cardfail.2021.05.026.
  • Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program.Akwo EA, Robinson-Cohen C, Chung CP, Shah SC, Brown NJ, Ikizler TA, Wilson OD, Rowan BX, Shuey MM, Siew ED, Luther JM, Giri A, Hellwege JN, Velez Edwards DR, Roumie CL, Tao R, Tsao PS, Gaziano JM, Wilson PWF, O'Donnell CJ, Edwards TL, Kovesdy CP, Hung AM. Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. Hypertension 2021, 78: 376-386. PMID: 34148359, PMCID: PMC8364328, DOI: 10.1161/HYPERTENSIONAHA.120.16181.
  • GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans.Luther JM, Ray J, Wei D, Koethe JR, Hannah L, DeMatteo A, Manning R, Terker AS, Peng D, Nian H, Yu C, Mashayekhi M, Gamboa J, Brown NJ. GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans. Hypertension 2021, 78: 1092-1102. PMID: 34455816, PMCID: PMC8429121, DOI: 10.1161/HYPERTENSIONAHA.121.17659.
  • Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome.Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ. Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome. The Journal Of Clinical Endocrinology And Metabolism 2020, 105 PMID: 31529097, PMCID: PMC7947776, DOI: 10.1210/clinem/dgz028.
  • Intraoperative Oxidative Damage and Delirium after Cardiac Surgery.Lopez MG, Hughes CG, DeMatteo A, O'Neal JB, McNeil JB, Shotwell MS, Morse J, Petracek MR, Shah AS, Brown NJ, Billings FT. Intraoperative Oxidative Damage and Delirium after Cardiac Surgery. Anesthesiology 2020, 132: 551-561. PMID: 31770146, PMCID: PMC7015795, DOI: 10.1097/ALN.0000000000003016.
  • Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS.Vocat C, Dunand M, Hubers SA, Bourdillon N, Millet GP, Brown NJ, Wuerzner G, Grouzmann E, Eugster PJ. Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS. Analytical Chemistry 2020, 92: 859-866. PMID: 31790196, PMCID: PMC8541045, DOI: 10.1021/acs.analchem.9b03505.
  • Response to Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin".Wilson JR, Shuey MM, Brown NJ, Devin JK. Response to Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin". Journal Of The Endocrine Society 2020, 4: bvaa006. PMID: 32133430, PMCID: PMC7049288, DOI: 10.1210/jendso/bvaa006.
  • Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data.Shuey M, Perkins B, Nian H, Yu C, Luther JM, Brown N. Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data. BMJ Open 2020, 10: e033100. PMID: 32461291, PMCID: PMC7259833, DOI: 10.1136/bmjopen-2019-033100.
  • Promoting the success of women and minority physician-scientists in academic medicine: a dean's perspective.Brown NJ. Promoting the success of women and minority physician-scientists in academic medicine: a dean's perspective. The Journal Of Clinical Investigation 2020, 130: 6201-6203. PMID: 33021966, PMCID: PMC7685745, DOI: 10.1172/JCI144526.
  • Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema.Maroteau C, Kalhan Siddiqui M, Veluchamy A, Carr F, White M, Cassidy AJ, Baranova EV, Rasmussen ER, Eriksson N, Bloch KM, Brown NJ, Bygum A, Hallberg P, Karawajczyk M, Magnusson PKE, Yue QY, Syvänen AC, von Buchwald C, Alfirevic A, Maitland-van der Zee AH, Wadelius M, Palmer CNA. Exome Sequencing Reveals Common and Rare Variants in F5 Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema. Clinical Pharmacology And Therapeutics 2020, 108: 1195-1202. PMID: 32496628, DOI: 10.1002/cpt.1927.
  • Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis.Gamboa JL, Roshanravan B, Towse T, Keller CA, Falck AM, Yu C, Frontera WR, Brown NJ, Ikizler TA. Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis. Clinical Journal Of The American Society Of Nephrology : CJASN 2020, 15: 926-936. PMID: 32591419, PMCID: PMC7341789, DOI: 10.2215/CJN.10320819.
  • Early urine electrolyte patterns in patients with acute heart failure.Collins SP, Jenkins CA, Baughman A, Miller KF, Storrow AB, Han JH, Brown NJ, Liu D, Luther JM, McNaughton CD, Self WH, Peng D, Testani JM, Lindenfeld J. Early urine electrolyte patterns in patients with acute heart failure. ESC Heart Failure 2019, 6: 80-88. PMID: 30295437, PMCID: PMC6351901, DOI: 10.1002/ehf2.12368.
  • Mineralocorticoid Receptor Activation and Atrial Fibrosis.Brown NJ. Mineralocorticoid Receptor Activation and Atrial Fibrosis. Hypertension 2019, 73: 294-295. PMID: 30595119, PMCID: PMC6404541, DOI: 10.1161/HYPERTENSIONAHA.118.11604.
  • Adipose Tissue in Persons With HIV Is Enriched for CD4+ T Effector Memory and T Effector Memory RA+ Cells, Which Show Higher CD69 Expression and CD57, CX3CR1, GPR56 Co-expression With Increasing Glucose Intolerance.Wanjalla CN, McDonnell WJ, Barnett L, Simmons JD, Furch BD, Lima MC, Woodward BO, Fan R, Fei Y, Baker PG, Ram R, Pilkinton MA, Mashayekhi M, Brown NJ, Mallal SA, Kalams SA, Koethe JR. Adipose Tissue in Persons With HIV Is Enriched for CD4+ T Effector Memory and T Effector Memory RA+ Cells, Which Show Higher CD69 Expression and CD57, CX3CR1, GPR56 Co-expression With Increasing Glucose Intolerance. Frontiers In Immunology 2019, 10: 408. PMID: 30941121, PMCID: PMC6433850, DOI: 10.3389/fimmu.2019.00408.
  • Higher urinary cortisol levels associate with increased cardiovascular risk.Haas AV, Hopkins PN, Brown NJ, Pojoga LH, Williams JS, Adler GK, Williams GH. Higher urinary cortisol levels associate with increased cardiovascular risk. Endocrine Connections 2019, 8: 634-640. PMID: 31018177, PMCID: PMC6528405, DOI: 10.1530/EC-19-0182.
  • Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition.Wilson JR, Kerman SJ, Hubers SA, Yu C, Nian H, Grouzmann E, Eugster PJ, Mayfield DS, Brown NJ. Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition. Journal Of The Endocrine Society 2019, 3: 1784-1798. PMID: 31528826, PMCID: PMC6734191, DOI: 10.1210/js.2019-00185.
  • Transformation to Academic Leadership: The Role of Mentorship and Executive Coaching.Rathmell WK, Brown NJ, Kilburg RR. Transformation to Academic Leadership: The Role of Mentorship and Executive Coaching. Consulting Psychology Journal 2019, 71: 141-160. PMID: 31787830, PMCID: PMC6884359, DOI: 10.1037/cpb0000124.
  • U.S. Physician-Scientist Workforce in the 21st Century: Recommendations to Attract and Sustain the Pipeline.Salata RA, Geraci MW, Rockey DC, Blanchard M, Brown NJ, Cardinal LJ, Garcia M, Madaio MP, Marsh JD, Todd RF. U.S. Physician-Scientist Workforce in the 21st Century: Recommendations to Attract and Sustain the Pipeline. Academic Medicine : Journal Of The Association Of American Medical Colleges 2018, 93: 565-573. PMID: 28991849, PMCID: PMC5882605, DOI: 10.1097/ACM.0000000000001950.
  • Two Pools of Epoxyeicosatrienoic Acids in Humans: Alterations in Salt-Sensitive Normotensive Subjects.Elijovich F, Milne GL, Brown NJ, Laniado-Schwartzman M, Laffer CL. Two Pools of Epoxyeicosatrienoic Acids in Humans: Alterations in Salt-Sensitive Normotensive Subjects. Hypertension 2018, 71: 346-355. PMID: 29279315, PMCID: PMC5764817, DOI: 10.1161/HYPERTENSIONAHA.117.10392.
  • Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women.Wilson JR, Brown NJ, Nian H, Yu C, Bidlingmaier M, Devin JK. Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women. Journal Of The American Heart Association 2018, 7 PMID: 29478970, PMCID: PMC5866333, DOI: 10.1161/JAHA.117.008000.
  • Fish Oil Supplementation Does Not Affect Cognitive Outcomes in Cardiac Surgery Patients in the Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) Trial.Jackson JC, Mozaffarian D, Graves AJ, Brown NJ, Marchioli R, Kiehl AL, Ely EW. Fish Oil Supplementation Does Not Affect Cognitive Outcomes in Cardiac Surgery Patients in the Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) Trial. The Journal Of Nutrition 2018, 148: 472-479. PMID: 29546292, PMCID: PMC6454465, DOI: 10.1093/jn/nxx002.
  • The Vasculature in Prediabetes.Wasserman DH, Wang TJ, Brown NJ. The Vasculature in Prediabetes. Circulation Research 2018, 122: 1135-1150. PMID: 29650631, PMCID: PMC5901903, DOI: 10.1161/CIRCRESAHA.118.311912.
  • Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.Kaseda R, Tsuchida Y, Gamboa JL, Zhong J, Zhang L, Yang H, Dikalova A, Bian A, Davies S, Fogo AF, Linton MF, Brown NJ, Ikizler TA, Kon V. Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis. Nutrition, Metabolism, And Cardiovascular Diseases : NMCD 2018, 28: 582-591. PMID: 29691148, PMCID: PMC5959764, DOI: 10.1016/j.numecd.2018.02.020.
  • Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case-control study.Shuey MM, Gandelman JS, Chung CP, Nian H, Yu C, Denny JC, Brown NJ. Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case-control study. BMJ Open 2018, 8: e021640. PMID: 29950471, PMCID: PMC6020960, DOI: 10.1136/bmjopen-2018-021640.
  • DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition.Hubers SA, Wilson JR, Yu C, Nian H, Grouzmann E, Eugster P, Shibao CA, Billings FT, Jafarian Kerman S, Brown NJ. DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide Y) in Humans During Renin-Angiotensin-Aldosterone System Inhibition. Hypertension 2018, 72: 712-719. PMID: 29987109, PMCID: PMC6202157, DOI: 10.1161/HYPERTENSIONAHA.118.11498.
  • Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema.Hubers S, Kohm K, Wei S, Yu C, Nian H, Grabert R, Sexton DJ, Brown NJ. Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema. The Journal Of Allergy And Clinical Immunology 2018, 142: 1636-1639.e5. PMID: 30036596, PMCID: PMC6226317, DOI: 10.1016/j.jaci.2018.06.037.
  • Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial.Zic JA, Straka BT, McGirt LY, Nian H, Yu C, Brown NJ. Aprepitant for the Treatment of Pruritus in Sézary Syndrome: A Randomized Crossover Clinical Trial. JAMA Dermatology 2018, 154: 1221-1222. PMID: 30140912, PMCID: PMC6233739, DOI: 10.1001/jamadermatol.2018.2510.
  • Developing Physician-Scientists.Brown NJ. Developing Physician-Scientists. Circulation Research 2018, 123: 645-647. PMID: 30355239, PMCID: PMC6324572, DOI: 10.1161/CIRCRESAHA.118.313473.
  • Fish Oil and Perioperative Bleeding.Akintoye E, Sethi P, Harris WS, Thompson PA, Marchioli R, Tavazzi L, Latini R, Pretorius M, Brown NJ, Libby P, Mozaffarian D. Fish Oil and Perioperative Bleeding. Circulation. Cardiovascular Quality And Outcomes 2018, 11: e004584. PMID: 30571332, PMCID: PMC6376981, DOI: 10.1161/CIRCOUTCOMES.118.004584.
  • Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema.Straka BT, Ramirez CE, Byrd JB, Stone E, Woodard-Grice A, Nian H, Yu C, Banerji A, Brown NJ. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. The Journal Of Allergy And Clinical Immunology 2017, 140: 242-248.e2. PMID: 27913306, PMCID: PMC5705179, DOI: 10.1016/j.jaci.2016.09.051.
  • Pharmacogenomics of off-target adverse drug reactions.Garon SL, Pavlos RK, White KD, Brown NJ, Stone CA, Phillips EJ. Pharmacogenomics of off-target adverse drug reactions. British Journal Of Clinical Pharmacology 2017, 83: 1896-1911. PMID: 28345177, PMCID: PMC5555876, DOI: 10.1111/bcp.13294.
  • Genetic Effects on the Correlation Structure of CVD Risk Factors: Exome-Wide Data From a Ghanaian Population.Kodaman N, Sobota RS, Asselbergs FW, Oetjens MT, Moore JH, Brown NJ, Aldrich MC, Williams SM. Genetic Effects on the Correlation Structure of CVD Risk Factors: Exome-Wide Data From a Ghanaian Population. Global Heart 2017, 12: 133-140. PMID: 28408189, PMCID: PMC5642993, DOI: 10.1016/j.gheart.2017.01.013.
  • Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery.Shuey MM, Billings FT, Wei S, Milne GL, Nian H, Yu C, Brown NJ. Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery. PloS One 2017, 12: e0175292. PMID: 28552948, PMCID: PMC5446112, DOI: 10.1371/journal.pone.0175292.
  • Systolic Blood Pressure and Biochemical Assessment of Adherence: A Cross-Sectional Analysis in the Emergency Department.McNaughton CD, Brown NJ, Rothman RL, Liu D, Kabagambe EK, Levy PD, Self WH, Storrow AB, Collins SP, Roumie CL. Systolic Blood Pressure and Biochemical Assessment of Adherence: A Cross-Sectional Analysis in the Emergency Department. Hypertension 2017, 70: 307-314. PMID: 28652467, PMCID: PMC5531074, DOI: 10.1161/HYPERTENSIONAHA.117.09659.
  • Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema.Stone C, Brown NJ. Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. Immunology And Allergy Clinics Of North America 2017, 37: 483-495. PMID: 28687104, DOI: 10.1016/j.iac.2017.04.006.
  • Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin.Wilson JR, Shuey MM, Brown NJ, Devin JK. Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin. Journal Of The Endocrine Society 2017, 1: 1168-1178. PMID: 29264572, PMCID: PMC5686657, DOI: 10.1210/js.2017-00312.
  • Training basic, clinical, and translational scientists.Hartmann, K.E., Heitman, E., and N.J. Brown. Training basic, clinical, and translational scientists. In Principles of Clinical and Translational Science, 2nd edition, eds. D. Robertson and G.H. Williams, Elsevier, London, UK, 2016, pp. 637-647.
  • High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.Billings FT, Hendricks PA, Schildcrout JS, Shi Y, Petracek MR, Byrne JG, Brown NJ. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial. JAMA 2016, 315: 877-88. PMID: 26906014, PMCID: PMC4843765, DOI: 10.1001/jama.2016.0548.
  • Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.Hubers SA, Brown NJ. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition. Circulation 2016, 133: 1115-24. PMID: 26976916, PMCID: PMC4800749, DOI: 10.1161/CIRCULATIONAHA.115.018622.
  • Heart failure event definitions in drug trials in patients with type 2 diabetes.Sharma A, Bhatt DL, Calvo G, Brown NJ, Zannad F, Mentz RJ. Heart failure event definitions in drug trials in patients with type 2 diabetes. The Lancet. Diabetes & Endocrinology 2016, 4: 294-6. PMID: 27016320, PMCID: PMC5221765, DOI: 10.1016/S2213-8587(16)00049-8.
  • B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS.Semler MW, Marney AM, Rice TW, Nian H, Yu C, Wheeler AP, Brown NJ. B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS. Chest 2016, 150: 102-11. PMID: 27018313, PMCID: PMC4980545, DOI: 10.1016/j.chest.2016.03.017.
  • Comparative effects of immediate-release and extended-release aspirin on basal and bradykinin-stimulated excretion of thromboxane and prostacyclin metabolites.Gamboa JL, Devin JK, Ramirez CE, Yu C, Nian H, Lee RH, Brown NJ. Comparative effects of immediate-release and extended-release aspirin on basal and bradykinin-stimulated excretion of thromboxane and prostacyclin metabolites. Pharmacology Research & Perspectives 2016, 4: e00221. PMID: 27069632, PMCID: PMC4804312, DOI: 10.1002/prp2.221.
  • Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study.Toh S, Hampp C, Reichman ME, Graham DJ, Balakrishnan S, Pucino F, Hamilton J, Lendle S, Iyer A, Rucker M, Pimentel M, Nathwani N, Griffin MR, Brown NJ, Fireman BH. Risk for Hospitalized Heart Failure Among New Users of Saxagliptin, Sitagliptin, and Other Antihyperglycemic Drugs: A Retrospective Cohort Study. Annals Of Internal Medicine 2016, 164: 705-14. PMID: 27110660, PMCID: PMC5178978, DOI: 10.7326/M15-2568.
  • Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease.Gamboa JL, Billings FT, Bojanowski MT, Gilliam LA, Yu C, Roshanravan B, Roberts LJ, Himmelfarb J, Ikizler TA, Brown NJ. Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. Physiological Reports 2016, 4 PMID: 27162261, PMCID: PMC4873632, DOI: 10.14814/phy2.12780.
  • Statins to Reduce Acute Kidney Injury After Cardiac Surgery--Reply.Billings FT, Brown NJ. Statins to Reduce Acute Kidney Injury After Cardiac Surgery--Reply. JAMA 2016, 316: 349-50. PMID: 27434456, DOI: 10.1001/jama.2016.6148.
  • Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition".Hubers SA, Brown NJ. Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition". Circulation 2016, 134: e11-2. PMID: 27436883, PMCID: PMC4957697, DOI: 10.1161/CIRCULATIONAHA.116.023311.
  • Epoxyeicosatrienoic acids and glucose homeostasis in mice and men.Luther JM, Brown NJ. Epoxyeicosatrienoic acids and glucose homeostasis in mice and men. Prostaglandins & Other Lipid Mediators 2016, 125: 2-7. PMID: 27448715, PMCID: PMC5035218, DOI: 10.1016/j.prostaglandins.2016.07.010.
  • Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition.Wilson JR, Brown NJ. Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition. Hypertension 2016, 68: 549-51. PMID: 27480841, PMCID: PMC4982800, DOI: 10.1161/HYPERTENSIONAHA.116.07884.
  • Plasminogen Activator Inhibitor-1 and Diagnosis of the Metabolic Syndrome in a West African Population.Kodaman N, Aldrich MC, Sobota R, Asselbergs FW, Brown NJ, Moore JH, Williams SM. Plasminogen Activator Inhibitor-1 and Diagnosis of the Metabolic Syndrome in a West African Population. Journal Of The American Heart Association 2016, 5 PMID: 27697752, PMCID: PMC5121488, DOI: 10.1161/JAHA.116.003867.
  • Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study.Kodaman N, Aldrich MC, Sobota R, Asselbergs FW, Poku KA, Brown NJ, Moore JH, Williams SM. Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study. PloS One 2016, 11: e0162753. PMID: 27732601, PMCID: PMC5061429, DOI: 10.1371/journal.pone.0162753.
  • Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial.Wu JH, Marchioli R, Silletta MG, Masson S, Sellke FW, Libby P, Milne GL, Brown NJ, Lombardi F, Damiano RJ, Marsala J, Rinaldi M, Domenech A, Simon C, Tavazzi L, Mozaffarian D. Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial. Journal Of The American Heart Association 2015, 4 PMID: 25994442, PMCID: PMC4599415, DOI: 10.1161/JAHA.115.001886.
  • Phenotype-Driven Plasma Biobanking Strategies and Methods.Bowton EA, Collier SP, Wang X, Sutcliffe CB, Van Driest SL, Couch LJ, Herrera M, Jerome RN, Slebos RJ, Alborn WE, Liebler DC, McNaughton CD, Mernaugh RL, Wells QS, Brown NJ, Roden DM, Pulley JM. Phenotype-Driven Plasma Biobanking Strategies and Methods. Journal Of Personalized Medicine 2015, 5: 140-52. PMID: 26110578, PMCID: PMC4493492, DOI: 10.3390/jpm5020140.
  • Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population.White MJ, Kodaman NM, Harder RH, Asselbergs FW, Vaughan DE, Brown NJ, Moore JH, Williams SM. Genetics of Plasminogen Activator Inhibitor-1 (PAI-1) in a Ghanaian Population. PloS One 2015, 10: e0136379. PMID: 26322636, PMCID: PMC4556460, DOI: 10.1371/journal.pone.0136379.
  • A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics.Baudrand R, Goodarzi MO, Vaidya A, Underwood PC, Williams JS, Jeunemaitre X, Hopkins PN, Brown N, Raby BA, Lasky-Su J, Adler GK, Cui J, Guo X, Taylor KD, Chen YD, Xiang A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH, Pojoga LH. A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics. Metabolism: Clinical And Experimental 2015, 64: 1674-81. PMID: 26475177, PMCID: PMC4641791, DOI: 10.1016/j.metabol.2015.09.005.
  • Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.Gamboa JL, Pretorius M, Sprinkel KC, Brown NJ, Ikizler TA. Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study. BMC Nephrology 2015, 16: 167. PMID: 26494370, PMCID: PMC4618919, DOI: 10.1186/s12882-015-0162-x.
  • Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial.Ramirez CE, Nian H, Yu C, Gamboa JL, Luther JM, Brown NJ, Shibao CA. Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial. The Journal Of Clinical Endocrinology And Metabolism 2015, 100: 4533-40. PMID: 26580240, PMCID: PMC4667163, DOI: 10.1210/jc.2015-3415.
  • Angiotensin-neprilysin inhibition versus enalapril in heart failure.McMurray, J.J., M. Packer, A.S. Desai, J. Gong, M.P. Lefkowitz, A.R. Riskala, J.L. Rouleau, V.C. Shi, S.D. Solomon, K. Swedberg, and M.R. Zile. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine 2014, 371:993-1004. (Member of the Angioedema Adjudication Committee)
  • Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.Devin JK, Pretorius M, Nian H, Yu C, Billings FT, Brown NJ. Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension 2014, 63: 951-7. PMID: 24516103, PMCID: PMC3984385, DOI: 10.1161/HYPERTENSIONAHA.113.02767.
  • Changes in B-type natriuretic peptide and BMI following Roux-en-Y gastric bypass surgery.Marney AM, Brown NJ, Tamboli R, Abumrad N. Changes in B-type natriuretic peptide and BMI following Roux-en-Y gastric bypass surgery. Diabetes Care 2014, 37: e70-1. PMID: 24652734, PMCID: PMC3964493, DOI: 10.2337/dc13-2449.
  • Quantitative Imaging of Preamyloid Oligomers, a Novel Structural Abnormality, in Human Atrial Samples.Sidorova TN, Mace LC, Wells KS, Yermalitskaya LV, Su PF, Shyr Y, Byrne JG, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Glabe CG, Brown NJ, Barnett JV, Murray KT. Quantitative Imaging of Preamyloid Oligomers, a Novel Structural Abnormality, in Human Atrial Samples. The Journal Of Histochemistry And Cytochemistry : Official Journal Of The Histochemistry Society 2014, 62: 479-87. PMID: 24789805, PMCID: PMC4072180, DOI: 10.1369/0022155414535782.
  • Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans.Luther JM, Byrne LM, Yu C, Wang TJ, Brown NJ. Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans. The Journal Of Clinical Endocrinology And Metabolism 2014, 99: E1895-902. PMID: 25029426, PMCID: PMC4184066, DOI: 10.1210/jc.2014-2122.
  • Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans.Laffer CL, Elijovich F, Eckert GJ, Tu W, Pratt JH, Brown NJ. Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans. Journal Of The American Society Of Hypertension : JASH 2014, 8: 475-80. PMID: 25064769, PMCID: PMC4115247, DOI: 10.1016/j.jash.2014.04.011.
  • Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.Devin JK, Pretorius M, Nian H, Yu C, Billings FT, Brown NJ. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm. Journal Of The American Heart Association 2014, 3 PMID: 25158865, PMCID: PMC4310400, DOI: 10.1161/JAHA.114.001075.
  • Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans.Ramirez CE, Shuey MM, Milne GL, Gilbert K, Hui N, Yu C, Luther JM, Brown NJ. Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. Prostaglandins & Other Lipid Mediators 2014, 113-115: 38-44. PMID: 25173047, PMCID: PMC4253976, DOI: 10.1016/j.prostaglandins.2014.08.001.
  • Hypertension is associated with preamyloid oligomers in human atrium: a missing link in atrial pathophysiology?Sidorova TN, Mace LC, Wells KS, Yermalitskaya LV, Su PF, Shyr Y, Atkinson JB, Fogo AB, Prinsen JK, Byrne JG, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Glabe CG, Brown NJ, Barnett JV, Murray KT. Hypertension is associated with preamyloid oligomers in human atrium: a missing link in atrial pathophysiology? Journal Of The American Heart Association 2014, 3: e001384. PMID: 25468655, PMCID: PMC4338732, DOI: 10.1161/JAHA.114.001384.
  • CYP4A11 variant is associated with high-density lipoprotein cholesterol in women.White CC, Feng Q, Cupples LA, Gainer JV, Dawson EP, Wilke RA, Brown NJ. CYP4A11 variant is associated with high-density lipoprotein cholesterol in women. The Pharmacogenomics Journal 2013, 13: 44-51. PMID: 21912424, PMCID: PMC3380161, DOI: 10.1038/tpj.2011.40.
  • Polymorphisms in the serum- and glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake.Rao AD, Sun B, Saxena A, Hopkins PN, Jeunemaitre X, Brown NJ, Adler GK, Williams JS. Polymorphisms in the serum- and glucocorticoid-inducible kinase 1 gene are associated with blood pressure and renin response to dietary salt intake. Journal Of Human Hypertension 2013, 27: 176-80. PMID: 22648267, PMCID: PMC3463709, DOI: 10.1038/jhh.2012.22.
  • Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial.Balaguer JM, Yu C, Byrne JG, Ball SK, Petracek MR, Brown NJ, Pretorius M. Contribution of endogenous bradykinin to fibrinolysis, inflammation, and blood product transfusion following cardiac surgery: a randomized clinical trial. Clinical Pharmacology And Therapeutics 2013, 93: 326-34. PMID: 23361105, PMCID: PMC4031681, DOI: 10.1038/clpt.2012.249.
  • Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension.Gilbert K, Nian H, Yu C, Luther JM, Brown NJ. Fenofibrate lowers blood pressure in salt-sensitive but not salt-resistant hypertension. Journal Of Hypertension 2013, 31: 820-9. PMID: 23385647, PMCID: PMC3800119, DOI: 10.1097/HJH.0b013e32835e8227.
  • The effect of reducing maximum shift lengths to 16 hours on internal medicine interns' educational opportunities.Theobald CN, Stover DG, Choma NN, Hathaway J, Green JK, Peterson NB, Sponsler KC, Vasilevskis EE, Kripalani S, Sergent J, Brown NJ, Denny JC. The effect of reducing maximum shift lengths to 16 hours on internal medicine interns' educational opportunities. Academic Medicine : Journal Of The Association Of American Medical Colleges 2013, 88: 512-8. PMID: 23425987, PMCID: PMC3638874, DOI: 10.1097/ACM.0b013e318285800f.
  • Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis.Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nature Reviews. Nephrology 2013, 9: 459-69. PMID: 23774812, PMCID: PMC3922409, DOI: 10.1038/nrneph.2013.110.
  • Introduction. P450 metabolites of arachidonic acid--from biochemistry to therapy.Brown NJ, Falck JR. Introduction. P450 metabolites of arachidonic acid--from biochemistry to therapy. Prostaglandins & Other Lipid Mediators 2013, 104-105: 1. PMID: 23809194, DOI: 10.1016/j.prostaglandins.2013.06.003.
  • Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Grice A, Teo KK, Anand SS, Zuvich RL, Bradford Y, Ross S, Nakamura Y, Ritchie M, Brown NJ. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenetics And Genomics 2013, 23: 470-8. PMID: 23838604, PMCID: PMC3904664, DOI: 10.1097/FPC.0b013e328363c137.
  • Developing physician-scientists: a perspective.Brown NJ. Developing physician-scientists: a perspective. Transactions Of The American Clinical And Climatological Association 2013, 124: 218-29. PMID: 23874028, PMCID: PMC3715951.
  • An LC-MS assay for the screening of cardiovascular medications in human samples.Dias E, Hachey B, McNaughton C, Nian H, Yu C, Straka B, Brown NJ, Caprioli RM. An LC-MS assay for the screening of cardiovascular medications in human samples. Journal Of Chromatography. B, Analytical Technologies In The Biomedical And Life Sciences 2013, 937: 44-53. PMID: 24013190, PMCID: PMC3800555, DOI: 10.1016/j.jchromb.2013.08.010.
  • Plasma phospholipid omega-3 fatty acids and incidence of postoperative atrial fibrillation in the OPERA trial.Wu JH, Marchioli R, Silletta MG, Macchia A, Song X, Siscovick DS, Harris WS, Masson S, Latini R, Albert C, Brown NJ, Lamarra M, Favaloro RR, Mozaffarian D. Plasma phospholipid omega-3 fatty acids and incidence of postoperative atrial fibrillation in the OPERA trial. Journal Of The American Heart Association 2013, 2: e000397. PMID: 24145742, PMCID: PMC3835252, DOI: 10.1161/JAHA.113.000397.
  • Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema.Straka B, Nian H, Sloan C, Byrd JB, Woodard-Grice A, Yu C, Stone E, Steven G, Hartert T, Teo KK, Pare G, McCarty CA, Brown NJ. Pollen count and presentation of angiotensin-converting enzyme inhibitor-associated angioedema. The Journal Of Allergy And Clinical Immunology. In Practice 2013, 1: 468-73.e1-4. PMID: 24565618, PMCID: PMC4042396, DOI: 10.1016/j.jaip.2013.05.003.
  • Prospective study of the incidence and predictors of thrombus in children undergoing palliative surgery for single ventricle physiology.Todd Tzanetos DR, Yu C, Hernanz-Schulman M, Barr FE, Brown NJ. Prospective study of the incidence and predictors of thrombus in children undergoing palliative surgery for single ventricle physiology. Intensive Care Medicine 2012, 38: 105-12. PMID: 21979273, PMCID: PMC4747610, DOI: 10.1007/s00134-011-2378-y.
  • Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, Brown NJ. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. Journal Of The American Society Of Nephrology : JASN 2012, 23: 334-42. PMID: 22158433, PMCID: PMC3269170, DOI: 10.1681/ASN.2011030287.
  • Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome.Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension 2012, 59: 893-8. PMID: 22353614, PMCID: PMC3402551, DOI: 10.1161/HYPERTENSIONAHA.111.189589.
  • Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans.Delaney JT, Jeff JM, Brown NJ, Pretorius M, Okafor HE, Darbar D, Roden DM, Crawford DC. Characterization of genome-wide association-identified variants for atrial fibrillation in African Americans. PloS One 2012, 7: e32338. PMID: 22384221, PMCID: PMC3285683, DOI: 10.1371/journal.pone.0032338.
  • Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies.Brown NJ. Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. Journal Of The American Society Of Hypertension : JASH 2012, 6: 163-8. PMID: 22433315, PMCID: PMC3422131, DOI: 10.1016/j.jash.2012.02.003.
  • Patient-oriented research in the era of personalized medicine.Brown NJ. Patient-oriented research in the era of personalized medicine. Clinical And Translational Science 2012, 5: 119-20. PMID: 22507115, PMCID: PMC5439745, DOI: 10.1111/j.1752-8062.2011.00394.x.
  • Lysine-specific demethylase 1: an epigenetic regulator of salt-sensitive hypertension.Williams JS, Chamarthi B, Goodarzi MO, Pojoga LH, Sun B, Garza AE, Raby BA, Adler GK, Hopkins PN, Brown NJ, Jeunemaitre X, Ferri C, Fang R, Leonor T, Cui J, Guo X, Taylor KD, Ida Chen YD, Xiang A, Raffel LJ, Buchanan TA, Rotter JI, Williams GH, Shi Y. Lysine-specific demethylase 1: an epigenetic regulator of salt-sensitive hypertension. American Journal Of Hypertension 2012, 25: 812-7. PMID: 22534796, PMCID: PMC3721725, DOI: 10.1038/ajh.2012.43.
  • Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass.Billings FT, Balaguer JM, C Y, Wright P, Petracek MR, Byrne JG, Brown NJ, Pretorius M. Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass. Clinical Pharmacology And Therapeutics 2012, 91: 1065-73. PMID: 22549281, PMCID: PMC3822756, DOI: 10.1038/clpt.2011.356.
  • Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury.Luther JM, Luo P, Wang Z, Cohen SE, Kim HS, Fogo AB, Brown NJ. Aldosterone deficiency and mineralocorticoid receptor antagonism prevent angiotensin II-induced cardiac, renal, and vascular injury. Kidney International 2012, 82: 643-51. PMID: 22622494, PMCID: PMC3434275, DOI: 10.1038/ki.2012.170.
  • Obesity and oxidative stress predict AKI after cardiac surgery.Billings FT, Pretorius M, Schildcrout JS, Mercaldo ND, Byrne JG, Ikizler TA, Brown NJ. Obesity and oxidative stress predict AKI after cardiac surgery. Journal Of The American Society Of Nephrology : JASN 2012, 23: 1221-8. PMID: 22626819, PMCID: PMC3380645, DOI: 10.1681/ASN.2011090940.
  • Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans.Marczak ED, Marzec J, Zeldin DC, Kleeberger SR, Brown NJ, Pretorius M, Lee CR. Polymorphisms in the transcription factor NRF2 and forearm vasodilator responses in humans. Pharmacogenetics And Genomics 2012, 22: 620-8. PMID: 22668754, PMCID: PMC3599320, DOI: 10.1097/FPC.0b013e32835516e5.
  • Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.Pretorius M, Murray KT, Yu C, Byrne JG, Billings FT, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Mishra V, Body SC, Brown NJ. Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Critical Care Medicine 2012, 40: 2805-12. PMID: 22824930, PMCID: PMC3588582, DOI: 10.1097/CCM.0b013e31825b8be2.
  • Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial.Mozaffarian, D., R. Marchioli, A. Macchia, M.G. Silletta, Ferrazzi P, T.J. Gardner, R. Latini, P. Libby, F. Lombardi, P.T. O'Gara, R.L. Page, L. Tavazzi, G. Tognoni G, and the OPERA Investigators. Fish oil and postoperative atrial fibrillation: the Omega-3 Fatty Acids for Prevention of Post-operative Atrial Fibrillation (OPERA) randomized trial. JAMA 2012, 308:2001-2011. PMC3694745
  • Low-salt diet increases insulin resistance in healthy subjects.Garg R, Williams GH, Hurwitz S, Brown NJ, Hopkins PN, Adler GK. Low-salt diet increases insulin resistance in healthy subjects. Metabolism: Clinical And Experimental 2011, 60: 965-8. PMID: 21036373, PMCID: PMC3036792, DOI: 10.1016/j.metabol.2010.09.005.
  • Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans.Lee CR, Pretorius M, Schuck RN, Burch LH, Bartlett J, Williams SM, Zeldin DC, Brown NJ. Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans. Hypertension 2011, 57: 116-22. PMID: 21098312, PMCID: PMC3020911, DOI: 10.1161/HYPERTENSIONAHA.110.161695.
  • Epistatic interactions in genetic regulation of t-PA and PAI-1 levels in a Ghanaian population.Penrod NM, Poku KA, Vaughan DE, Asselbergs FW, Brown NJ, Moore JH, Williams SM. Epistatic interactions in genetic regulation of t-PA and PAI-1 levels in a Ghanaian population. PloS One 2011, 6: e16639. PMID: 21304999, PMCID: PMC3031598, DOI: 10.1371/journal.pone.0016639.
  • Renin gene polymorphism: its relationship to hypertension, renin levels and vascular responses.Sun B, Williams JS, Pojoga L, Chamarthi B, Lasky-Su J, Raby BA, Hopkins PN, Jeunemaitre X, Brown NJ, Ferri C, Williams GH. Renin gene polymorphism: its relationship to hypertension, renin levels and vascular responses. Journal Of The Renin-angiotensin-aldosterone System : JRAAS 2011, 12: 564-71. PMID: 21490026, PMCID: PMC3444254, DOI: 10.1177/1470320311405873.
  • Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets.Luther JM, Luo P, Kreger MT, Brissova M, Dai C, Whitfield TT, Kim HS, Wasserman DH, Powers AC, Brown NJ. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 2011, 54: 2152-63. PMID: 21519965, PMCID: PMC3216479, DOI: 10.1007/s00125-011-2158-9.
  • The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians.Vaidya A, Sun B, Forman JP, Hopkins PN, Brown NJ, Kolatkar NS, Williams GH, Williams JS. The Fok1 vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians. Clinical Endocrinology 2011, 74: 783-90. PMID: 21521263, PMCID: PMC3089671, DOI: 10.1111/j.1365-2265.2011.03991.x.
  • This is not Dr. Conn's aldosterone anymore.Brown NJ. This is not Dr. Conn's aldosterone anymore. Transactions Of The American Clinical And Climatological Association 2011, 122: 229-43. PMID: 21686229, PMCID: PMC3116341.
  • Part-time physician faculty in a pediatrics department: a study of equity in compensation and academic advancement.Darbar M, Emans SJ, Harris ZL, Brown NJ, Scott TA, Cooper WO. Part-time physician faculty in a pediatrics department: a study of equity in compensation and academic advancement. Academic Medicine : Journal Of The Association Of American Medical Colleges 2011, 86: 968-73. PMID: 21694562, DOI: 10.1097/ACM.0b013e318222317e.
  • Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients.Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney International 2011, 80: 978-985. PMID: 21775975, PMCID: PMC3656595, DOI: 10.1038/ki.2011.228.
  • CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow.Williams JS, Hopkins PN, Jeunemaitre X, Brown NJ. CYP4A11 T8590C polymorphism, salt-sensitive hypertension, and renal blood flow. Journal Of Hypertension 2011, 29: 1913-8. PMID: 21873888, PMCID: PMC3309034, DOI: 10.1097/HJH.0b013e32834aa786.
  • The renin-angiotensin-aldosterone system and glucose homeostasis.Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends In Pharmacological Sciences 2011, 32: 734-9. PMID: 21880378, PMCID: PMC3223326, DOI: 10.1016/j.tips.2011.07.006.
  • Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but attenuates vascular tissue-type plasminogen activator release.Pretorius M, Brown NJ. Endogenous nitric oxide contributes to bradykinin-stimulated glucose uptake but attenuates vascular tissue-type plasminogen activator release. The Journal Of Pharmacology And Experimental Therapeutics 2010, 332: 291-7. PMID: 19841473, PMCID: PMC2802470, DOI: 10.1124/jpet.109.160168.
  • Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy.Saxena AR, Karumanchi SA, Brown NJ, Royle CM, McElrath TF, Seely EW. Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension 2010, 55: 1239-45. PMID: 20308605, PMCID: PMC2880505, DOI: 10.1161/HYPERTENSIONAHA.109.147595.
  • Aldosterone and inflammation.Gilbert KC, Brown NJ. Aldosterone and inflammation. Current Opinion In Endocrinology, Diabetes, And Obesity 2010, 17: 199-204. PMID: 20422780, PMCID: PMC4079531, DOI: 10.1097/med.0b013e3283391989.
  • Increased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism.Fong P, Stafforini DM, Brown NJ, Pretorius M. Increased blood flow induces oxidative stress through an endothelium- and nitric oxide-independent mechanism. Free Radical Biology & Medicine 2010, 49: 301-5. PMID: 20423727, PMCID: PMC2916026, DOI: 10.1016/j.freeradbiomed.2010.04.023.
  • Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro.Adam A, Montpas N, Keire D, Désormeaux A, Brown NJ, Marceau F, Westenberger B. Bradykinin forming capacity of oversulfated chondroitin sulfate contaminated heparin in vitro. Biomaterials 2010, 31: 5741-8. PMID: 20427081, PMCID: PMC2896062, DOI: 10.1016/j.biomaterials.2010.03.074.
  • Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use.Byrd JB, Woodard-Grice A, Stone E, Lucisano A, Schaefer H, Yu C, Eyler AE, Salloum NE, Brown NJ. Association of angiotensin-converting enzyme inhibitor-associated angioedema with transplant and immunosuppressant use. Allergy 2010, 65: 1381-7. PMID: 20557296, PMCID: PMC3305268, DOI: 10.1111/j.1398-9995.2010.02398.x.
  • Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery.Billings FT, Pretorius M, Siew ED, Yu C, Brown NJ. Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. Journal Of Cardiothoracic And Vascular Anesthesia 2010, 24: 913-20. PMID: 20599398, PMCID: PMC2992577, DOI: 10.1053/j.jvca.2010.03.024.
  • Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema.Woodard-Grice AV, Lucisano AC, Byrd JB, Stone ER, Simmons WH, Brown NJ. Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenetics And Genomics 2010, 20: 532-6. PMID: 20625347, PMCID: PMC2945219, DOI: 10.1097/FPC.0b013e32833d3acb.
  • The relationship between peroxisome proliferator-activated receptor-gamma and renin: a human genetics study.Underwood PC, Sun B, Williams JS, Pojoga LH, Chamarthi B, Lasky-Su J, Raby BA, Hopkins PN, Jeunemaitre X, Brown NJ, Adler GK, Williams GH. The relationship between peroxisome proliferator-activated receptor-gamma and renin: a human genetics study. The Journal Of Clinical Endocrinology And Metabolism 2010, 95: E75-9. PMID: 20631015, PMCID: PMC2936061, DOI: 10.1210/jc.2010-0270.
  • Therapeutic potential of plasminogen activator inhibitor-1 inhibitors.Brown NJ. Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. Therapeutic Advances In Cardiovascular Disease 2010, 4: 315-24. PMID: 20660535, DOI: 10.1177/1753944710379126.
  • Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.Marney A, Kunchakarra S, Byrne L, Brown NJ. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension 2010, 56: 728-33. PMID: 20679179, PMCID: PMC3305047, DOI: 10.1161/HYPERTENSIONAHA.110.156554.
  • Training basic, clinical, and translational scientists.Hartmann, K.E., Heitman, E., and N.J. Brown. Training basic, clinical, and translational scientists. In Principles of Clinical and Translational Science, eds. D. Robertson and G.H. Williams, Elsevier, London, UK, 2009, pp. 191-200.
  • Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry.Kim KM, Henderson GN, Frye RF, Galloway CD, Brown NJ, Segal MS, Imaram W, Angerhofer A, Johnson RJ. Simultaneous determination of uric acid metabolites allantoin, 6-aminouracil, and triuret in human urine using liquid chromatography-mass spectrometry. Journal Of Chromatography. B, Analytical Technologies In The Biomedical And Life Sciences 2009, 877: 65-70. PMID: 19081307, PMCID: PMC2684329, DOI: 10.1016/j.jchromb.2008.11.029.
  • Inhaled insulin is associated with prolonged enhancement of glucose disposal in muscle and liver in the canine.Edgerton DS, Cherrington AD, Neal DW, Scott M, Lautz M, Brown N, Petro J, Hobbs CH, Leach C, Del Parigi A, Strack TR. Inhaled insulin is associated with prolonged enhancement of glucose disposal in muscle and liver in the canine. The Journal Of Pharmacology And Experimental Therapeutics 2009, 328: 970-5. PMID: 19098161, PMCID: PMC3202424, DOI: 10.1124/jpet.108.146985.
  • Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta.Luther JM, Wang Z, Ma J, Makhanova N, Kim HS, Brown NJ. Endogenous aldosterone contributes to acute angiotensin II-stimulated plasminogen activator inhibitor-1 and preproendothelin-1 expression in heart but not aorta. Endocrinology 2009, 150: 2229-36. PMID: 19106220, PMCID: PMC2671907, DOI: 10.1210/en.2008-1296.
  • Salt in the wound.Brown NJ. Salt in the wound. Journal Of The American Society Of Nephrology : JASN 2009, 20: 5-6. PMID: 19118146, DOI: 10.1681/ASN.2008111185.
  • Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.Hill KD, Eckhauser AW, Marney A, Brown NJ. Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome. Diabetes Care 2009, 32: 857-9. PMID: 19196886, PMCID: PMC2671107, DOI: 10.2337/dc08-1862.
  • Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt.Lea WB, Kwak ES, Luther JM, Fowler SM, Wang Z, Ma J, Fogo AB, Brown NJ. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney International 2009, 75: 936-44. PMID: 19225557, PMCID: PMC2770712, DOI: 10.1038/ki.2009.9.
  • Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema.Brown NJ, Byiers S, Carr D, Maldonado M, Warner BA. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension 2009, 54: 516-23. PMID: 19581505, PMCID: PMC2758288, DOI: 10.1161/HYPERTENSIONAHA.109.134197.
  • Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis.Marney AM, Ma J, Luther JM, Ikizler TA, Brown NJ. Endogenous bradykinin contributes to increased plasminogen activator inhibitor 1 antigen following hemodialysis. Journal Of The American Society Of Nephrology : JASN 2009, 20: 2246-52. PMID: 19628666, PMCID: PMC2754101, DOI: 10.1681/ASN.2009050505.
  • Letter by Brown and Pretorius regarding article, "effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients".Brown NJ, Pretorius M. Letter by Brown and Pretorius regarding article, "effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients". Circulation 2009, 120: e159; author reply e160. PMID: 19901200, DOI: 10.1161/CIRCULATIONAHA.109.874743.
  • Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery.Body SC, Collard CD, Shernan SK, Fox AA, Liu KY, Ritchie MD, Perry TE, Muehlschlegel JD, Aranki S, Donahue BS, Pretorius M, Estrada JC, Ellinor PT, Newton-Cheh C, Seidman CE, Seidman JG, Herman DS, Lichtner P, Meitinger T, Pfeufer A, Kääb S, Brown NJ, Roden DM, Darbar D. Variation in the 4q25 chromosomal locus predicts atrial fibrillation after coronary artery bypass graft surgery. Circulation. Cardiovascular Genetics 2009, 2: 499-506. PMID: 20031626, PMCID: PMC2801871, DOI: 10.1161/CIRCGENETICS.109.849075.
  • Mineralocorticoid antagonists in heart failure and chronic renal failure.Brown, N.J. Mineralocorticoid antagonists in heart failure and chronic renal failure. In Sodium in hHealth and Disease, ed. M. Burnier, Informa Healthcare, New York, NY, 2008, pp. 433-446.
  • Tissue renin-angiotensin systems.Brown, N.J. Tissue renin-angiotensin systems. In Hypertension Primer, 4th edition eds. J.L. Izzo, D. Sica, and H.R. Black, Lippincott Williams and Wilkins, Philadelphia, PA, 2008, pp. 59-60.
  • The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance.Pretorius MM, Gainer JV, Van Guilder GP, Coelho EB, Luther JM, Fong P, Rosenbaum DD, Malave HA, Yu C, Ritchie MD, Vaughan DE, Brown NJ. The bradykinin type 2 receptor BE1 polymorphism and ethnicity influence systolic blood pressure and vascular resistance. Clinical Pharmacology And Therapeutics 2008, 83: 122-9. PMID: 17522594, DOI: 10.1038/sj.clpt.6100250.
  • Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema.Byrd JB, Touzin K, Sile S, Gainer JV, Yu C, Nadeau J, Adam A, Brown NJ. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension 2008, 51: 141-7. PMID: 18025295, PMCID: PMC2749928, DOI: 10.1161/HYPERTENSIONAHA.107.096552.
  • Aldosterone and vascular inflammation.Brown NJ. Aldosterone and vascular inflammation. Hypertension 2008, 51: 161-7. PMID: 18172061, DOI: 10.1161/HYPERTENSIONAHA.107.095489.
  • Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition.Van Guilder GP, Pretorius M, Luther JM, Byrd JB, Hill K, Gainer JV, Brown NJ. Bradykinin type 2 receptor BE1 genotype influences bradykinin-dependent vasodilation during angiotensin-converting enzyme inhibition. Hypertension 2008, 51: 454-9. PMID: 18180402, PMCID: PMC2581632, DOI: 10.1161/HYPERTENSIONAHA.107.102574.
  • The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension.Laffer CL, Gainer JV, Waterman MR, Capdevila JH, Laniado-Schwartzman M, Nasjletti A, Brown NJ, Elijovich F. The T8590C polymorphism of CYP4A11 and 20-hydroxyeicosatetraenoic acid in essential hypertension. Hypertension 2008, 51: 767-72. PMID: 18227405, PMCID: PMC2365894, DOI: 10.1161/HYPERTENSIONAHA.107.102921.
  • 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women.Pretorius M, van Guilder GP, Guzman RJ, Luther JM, Brown NJ. 17Beta-estradiol increases basal but not bradykinin-stimulated release of active t-PA in young postmenopausal women. Hypertension 2008, 51: 1190-6. PMID: 18259028, PMCID: PMC2673569, DOI: 10.1161/HYPERTENSIONAHA.107.105627.
  • Association of a CYP4A11 variant and blood pressure in black men.Gainer JV, Lipkowitz MS, Yu C, Waterman MR, Dawson EP, Capdevila JH, Brown NJ. Association of a CYP4A11 variant and blood pressure in black men. Journal Of The American Society Of Nephrology : JASN 2008, 19: 1606-12. PMID: 18385420, PMCID: PMC2488260, DOI: 10.1681/ASN.2008010063.
  • Centralized oversight of physician-scientist faculty development at Vanderbilt: early outcomes.Brown AM, Morrow JD, Limbird LE, Byrne DW, Gabbe SG, Balser JR, Brown NJ. Centralized oversight of physician-scientist faculty development at Vanderbilt: early outcomes. Academic Medicine : Journal Of The Association Of American Medical Colleges 2008, 83: 969-75. PMID: 18820531, PMCID: PMC3780596, DOI: 10.1097/ACM.0b013e3181850950.
  • Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery.Fleming GA, Murray KT, Yu C, Byrne JG, Greelish JP, Petracek MR, Hoff SJ, Ball SK, Brown NJ, Pretorius M. Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. Circulation 2008, 118: 1619-25. PMID: 18824641, PMCID: PMC2770257, DOI: 10.1161/CIRCULATIONAHA.108.790162.
  • Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population.Schoenhard JA, Asselbergs FW, Poku KA, Stocki SA, Gordon S, Vaughan DE, Brown NJ, Moore JH, Williams SM. Male-female differences in the genetic regulation of t-PA and PAI-1 levels in a Ghanaian population. Human Genetics 2008, 124: 479-88. PMID: 18953568, PMCID: PMC2770717, DOI: 10.1007/s00439-008-0573-x.
  • Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade.LeFebvre J, Shintani A, Gebretsadik T, Petro JR, Murphey LJ, Brown NJ. Bradykinin B(2) receptor does not contribute to blood pressure lowering during AT(1) receptor blockade. The Journal Of Pharmacology And Experimental Therapeutics 2007, 320: 1261-7. PMID: 17182977, DOI: 10.1124/jpet.106.117259.
  • Ala92 type 2 deiodinase allele increases risk for the development of hypertension.Gumieniak O, Perlstein TS, Williams JS, Hopkins PN, Brown NJ, Raby BA, Williams GH. Ala92 type 2 deiodinase allele increases risk for the development of hypertension. Hypertension 2007, 49: 461-6. PMID: 17224473, DOI: 10.1161/01.HYP.0000256295.72185.fd.
  • Urinary free cortisol: an intermediate phenotype and a potential genetic marker for a salt-resistant subset of essential hypertension.Chamarthi B, Kolatkar NS, Hunt SC, Williams JS, Seely EW, Brown NJ, Murphey LJ, Jeunemaitre X, Williams GH. Urinary free cortisol: an intermediate phenotype and a potential genetic marker for a salt-resistant subset of essential hypertension. The Journal Of Clinical Endocrinology And Metabolism 2007, 92: 1340-6. PMID: 17264181, DOI: 10.1210/jc.2006-2093.
  • Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid.Muldowney JA, Painter CA, Sanders-Bush E, Brown NJ, Vaughan DE. Acute tissue-type plasminogen activator release in human microvascular endothelial cells: the roles of Galphaq, PLC-beta, IP3 and 5,6-epoxyeicosatrienoic acid. Thrombosis And Haemostasis 2007, 97: 263-71. PMID: 17264956.
  • Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency.Brown NJ, Bradford J, Wang Z, Lea W, Ma L, Ma J, Vaughan DE, Fogo AB. Modulation of angiotensin II and norepinephrine-induced plasminogen activator inhibitor-1 expression by AT1a receptor deficiency. Kidney International 2007, 72: 72-81. PMID: 17429342, DOI: 10.1038/sj.ki.5002268.
  • Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema.Byrd JB, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T, Does MD, Brown NJ. Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. The Journal Of Allergy And Clinical Immunology 2007, 120: 403-8. PMID: 17531305, DOI: 10.1016/j.jaci.2007.04.012.
  • Aldosterone and end-organ damage.Marney AM, Brown NJ. Aldosterone and end-organ damage. Clinical Science (London, England : 1979) 2007, 113: 267-78. PMID: 17683282, DOI: 10.1042/CS20070123.
  • Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass.Pretorius M, Donahue BS, Yu C, Greelish JP, Roden DM, Brown NJ. Plasminogen activator inhibitor-1 as a predictor of postoperative atrial fibrillation after cardiopulmonary bypass. Circulation 2007, 116: I1-7. PMID: 17846288, DOI: 10.1161/CIRCULATIONAHA.106.677906.
  • Functional BSND variants in essential hypertension.Sile S, Gillani NB, Velez DR, Vanoye CG, Yu C, Byrne LM, Gainer JV, Brown NJ, Williams SM, George AL. Functional BSND variants in essential hypertension. American Journal Of Hypertension 2007, 20: 1176-1182. PMID: 17954364, DOI: 10.1016/j.amjhyper.2007.07.003.
  • A population-based study in Ghana to investigate inter-individual variation in plasma t-PA and PAI-1.Williams SM, Stocki S, Jiang L, Brew K, Gordon S, Vaughan DE, Brown NJ, Poku KA, Moore JH. A population-based study in Ghana to investigate inter-individual variation in plasma t-PA and PAI-1. Ethnicity & Disease 2007, 17: 492-7. PMID: 17985503.
  • Nancy J. Brown, M.D., Robert H. Williams Professor of Medicine and Pharmacology.Brown, N.J. Chapter 1: Nancy J. Brown, M.D., Robert H. Williams Professor of Medicine and Pharmacology. In What’s Past is Prologue, ed. Eric Neilson, Hillsboro Press, Franklin, TN, 2006, pp. 3-8.
  • Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia.Williams JS, Williams GH, Raji A, Jeunemaitre X, Brown NJ, Hopkins PN, Conlin PR. Prevalence of primary hyperaldosteronism in mild to moderate hypertension without hypokalaemia. Journal Of Human Hypertension 2006, 20: 129-36. PMID: 16292348, DOI: 10.1038/sj.jhh.1001948.
  • Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition.Brown NJ, Muldowney JA, Vaughan DE. Endogenous NO regulates plasminogen activator inhibitor-1 during angiotensin-converting enzyme inhibition. Hypertension 2006, 47: 441-8. PMID: 16432054, DOI: 10.1161/01.HYP.0000202478.79587.1a.
  • Blood pressure reduction and tissue-type plasminogen activator release.Brown NJ. Blood pressure reduction and tissue-type plasminogen activator release. Hypertension 2006, 47: 648-9. PMID: 16520404, DOI: 10.1161/01.HYP.0000209952.30603.e9.
  • Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury.Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney International 2006, 69: 1064-72. PMID: 16528256, DOI: 10.1038/sj.ki.5000201.
  • Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans.Murphey LJ, Malave HA, Petro J, Biaggioni I, Byrne DW, Vaughan DE, Luther JM, Pretorius M, Brown NJ. Bradykinin and its metabolite bradykinin 1-5 inhibit thrombin-induced platelet aggregation in humans. The Journal Of Pharmacology And Experimental Therapeutics 2006, 318: 1287-92. PMID: 16772538, DOI: 10.1124/jpet.106.104026.
  • Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension.Pojoga L, Kolatkar NS, Williams JS, Perlstein TS, Jeunemaitre X, Brown NJ, Hopkins PN, Raby BA, Williams GH. Beta-2 adrenergic receptor diplotype defines a subset of salt-sensitive hypertension. Hypertension 2006, 48: 892-900. PMID: 17015767, DOI: 10.1161/01.HYP.0000244688.45472.95.
  • Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism.Luther JM, Gainer JV, Murphey LJ, Yu C, Vaughan DE, Morrow JD, Brown NJ. Angiotensin II induces interleukin-6 in humans through a mineralocorticoid receptor-dependent mechanism. Hypertension 2006, 48: 1050-7. PMID: 17043157, DOI: 10.1161/01.HYP.0000248135.97380.76.
  • Angiotensin-converting enzyme inhibitor-associated angioedema.Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunology And Allergy Clinics Of North America 2006, 26: 725-37. PMID: 17085287, DOI: 10.1016/j.iac.2006.08.001.
  • Risk factor interactions and genetic effects associated with post-operative atrial fibrillation.Motsinger AA, Donahue BS, Brown NJ, Roden DM, Ritchie MD. Risk factor interactions and genetic effects associated with post-operative atrial fibrillation. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing 2006, 584-95. PMID: 17094271.
  • Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.Weisberg AD, Albornoz F, Griffin JP, Crandall DL, Elokdah H, Fogo AB, Vaughan DE, Brown NJ. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling. Arteriosclerosis, Thrombosis, And Vascular Biology 2005, 25: 365-71. PMID: 15576638, DOI: 10.1161/01.ATV.0000152356.85791.52.
  • Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension.Gainer JV, Bellamine A, Dawson EP, Womble KE, Grant SW, Wang Y, Cupples LA, Guo CY, Demissie S, O'Donnell CJ, Brown NJ, Waterman MR, Capdevila JH. Functional variant of CYP4A11 20-hydroxyeicosatetraenoic acid synthase is associated with essential hypertension. Circulation 2005, 111: 63-9. PMID: 15611369, DOI: 10.1161/01.CIR.0000151309.82473.59.
  • Aldosterone and end-organ damage.Brown NJ. Aldosterone and end-organ damage. Current Opinion In Nephrology And Hypertension 2005, 14: 235-41. PMID: 15821416, DOI: 10.1097/01.mnh.0000165889.60254.98.
  • Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension.King LM, Gainer JV, David GL, Dai D, Goldstein JA, Brown NJ, Zeldin DC. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenetics And Genomics 2005, 15: 7-13. PMID: 15864120, DOI: 10.1097/01213011-200501000-00002.
  • Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.Ma J, Albornoz F, Yu C, Byrne DW, Vaughan DE, Brown NJ. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance. Hypertension 2005, 46: 313-20. PMID: 15998706, DOI: 10.1161/01.HYP.0000174327.53863.86.
  • Proteomic patterns and prediction of glomerulosclerosis and its mechanisms.Xu BJ, Shyr Y, Liang X, Ma LJ, Donnert EM, Roberts JD, Zhang X, Kon V, Brown NJ, Caprioli RM, Fogo AB. Proteomic patterns and prediction of glomerulosclerosis and its mechanisms. Journal Of The American Society Of Nephrology : JASN 2005, 16: 2967-75. PMID: 16079267, DOI: 10.1681/ASN.2005030262.
  • Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men.Pretorius M, Luther JM, Murphey LJ, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases basal vascular tissue plasminogen activator release in women but not in men. Arteriosclerosis, Thrombosis, And Vascular Biology 2005, 25: 2435-40. PMID: 16166566, DOI: 10.1161/01.ATV.0000186185.13977.94.
  • A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors.Duan QL, Nikpoor B, Dube MP, Molinaro G, Meijer IA, Dion P, Rochefort D, Saint-Onge J, Flury L, Brown NJ, Gainer JV, Rouleau JL, Agostoni A, Cugno M, Simon P, Clavel P, Potier J, Wehbe B, Benarbia S, Marc-Aurele J, Chanard J, Foroud T, Adam A, Rouleau GA. A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. American Journal Of Human Genetics 2005, 77: 617-26. PMID: 16175507, PMCID: PMC1275610, DOI: 10.1086/496899.
  • The kallikrein-kinin system: current and future pharmacological targets.Moreau ME, Garbacki N, Molinaro G, Brown NJ, Marceau F, Adam A. The kallikrein-kinin system: current and future pharmacological targets. Journal Of Pharmacological Sciences 2005, 99: 6-38. PMID: 16177542, DOI: 10.1254/jphs.srj05001x.
  • Regression of existing glomerulosclerosis by inhibition of aldosterone.Aldigier JC, Kanjanbuch T, Ma LJ, Brown NJ, Fogo AB. Regression of existing glomerulosclerosis by inhibition of aldosterone. Journal Of The American Society Of Nephrology : JASN 2005, 16: 3306-14. PMID: 16192423, DOI: 10.1681/ASN.2004090804.
  • A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass.Pretorius M, Scholl FG, McFarlane JA, Murphey LJ, Brown NJ. A pilot study indicating that bradykinin B2 receptor antagonism attenuates protamine-related hypotension after cardiopulmonary bypass. Clinical Pharmacology And Therapeutics 2005, 78: 477-85. PMID: 16321614, DOI: 10.1016/j.clpt.2005.08.010.
  • An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation.Coffey CS, Hebert PR, Ritchie MD, Krumholz HM, Gaziano JM, Ridker PM, Brown NJ, Vaughan DE, Moore JH. An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. BMC Bioinformatics 2004, 5: 49. PMID: 15119966, PMCID: PMC419697, DOI: 10.1186/1471-2105-5-49.
  • Relationship between carbamoyl-phosphate synthetase genotype and systemic vascular function.Summar ML, Gainer JV, Pretorius M, Malave H, Harris S, Hall LD, Weisberg A, Vaughan DE, Christman BW, Brown NJ. Relationship between carbamoyl-phosphate synthetase genotype and systemic vascular function. Hypertension 2004, 43: 186-91. PMID: 14718356, DOI: 10.1161/01.HYP.0000112424.06921.52.
  • Loss of sodium modulation of plasma kinins in human hypertension.Murphey LJ, Eccles WK, Williams GH, Brown NJ. Loss of sodium modulation of plasma kinins in human hypertension. The Journal Of Pharmacology And Experimental Therapeutics 2004, 308: 1046-52. PMID: 14718610, DOI: 10.1124/jpet.103.059337.
  • Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.Ma LJ, Mao SL, Taylor KL, Kanjanabuch T, Guan Y, Zhang Y, Brown NJ, Swift LL, McGuinness OP, Wasserman DH, Vaughan DE, Fogo AB. Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1. Diabetes 2004, 53: 336-46. PMID: 14747283, DOI: 10.2337/diabetes.53.2.336.
  • Environmentally determined genetic expression: clinical correlates with molecular variants of carbamyl phosphate synthetase I.Summar ML, Hall L, Christman B, Barr F, Smith H, Kallianpur A, Brown N, Yadav M, Willis A, Eeds A, Cermak E, Summar S, Wilson A, Arvin M, Putnam A, Wills M, Cunningham G. Environmentally determined genetic expression: clinical correlates with molecular variants of carbamyl phosphate synthetase I. Molecular Genetics And Metabolism 2004, 81 Suppl 1: S12-9. PMID: 15050969, DOI: 10.1016/j.ymgme.2003.11.014.
  • The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1.Nieman MT, Warnock M, Hasan AA, Mahdi F, Lucchesi BR, Brown NJ, Murphey LJ, Schmaier AH. The preparation and characterization of novel peptide antagonists to thrombin and factor VIIa and activation of protease-activated receptor 1. The Journal Of Pharmacology And Experimental Therapeutics 2004, 311: 492-501. PMID: 15210836, DOI: 10.1124/jpet.104.069229.
  • Established and emerging plasma biomarkers in the prediction of first atherothrombotic events.Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 2004, 109: IV6-19. PMID: 15226246, DOI: 10.1161/01.CIR.0000133444.17867.56.
  • Thyroid function and blood pressure homeostasis in euthyroid subjects.Gumieniak O, Perlstein TS, Hopkins PN, Brown NJ, Murphey LJ, Jeunemaitre X, Hollenberg NK, Williams GH. Thyroid function and blood pressure homeostasis in euthyroid subjects. The Journal Of Clinical Endocrinology And Metabolism 2004, 89: 3455-61. PMID: 15240631, DOI: 10.1210/jc.2003-032143.
  • NO synthase inhibition increases aldosterone in humans.Muldowney JA, Davis SN, Vaughan DE, Brown NJ. NO synthase inhibition increases aldosterone in humans. Hypertension 2004, 44: 739-45. PMID: 15381675, DOI: 10.1161/01.HYP.0000143852.48258.f1.
  • Uric acid and the state of the intrarenal renin-angiotensin system in humans.Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, Fisher ND. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney International 2004, 66: 1465-70. PMID: 15458439, DOI: 10.1111/j.1523-1755.2004.00909.x.
  • Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass.Pretorius M, McFarlane JA, Vaughan DE, Brown NJ, Murphey LJ. Angiotensin-converting enzyme inhibition and smoking potentiate the kinin response to cardiopulmonary bypass. Clinical Pharmacology And Therapeutics 2004, 76: 379-87. PMID: 15470338, DOI: 10.1016/j.clpt.2004.06.004.
  • Contribution of bradykinin to the cardioprotective effects of ACE inhibitors.Murphey, L.J., D.E. Vaughan, and N.J. Brown. Contribution of bradykinin to the cardioprotective effects of ACE inhibitors. European Heart Journal 2003, 5:A37-A41.
  • Characterization of the CYP4A11 gene, a second CYP4A gene in humans.Bellamine A, Wang Y, Waterman MR, Gainer JV, Dawson EP, Brown NJ, Capdevila JH. Characterization of the CYP4A11 gene, a second CYP4A gene in humans. Archives Of Biochemistry And Biophysics 2003, 409: 221-7. PMID: 12464262, DOI: 10.1016/s0003-9861(02)00545-3.
  • Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin.Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition increases human vascular tissue-type plasminogen activator release through endogenous bradykinin. Circulation 2003, 107: 579-85. PMID: 12566370, DOI: 10.1161/01.cir.0000046268.59922.a4.
  • Eplerenone: cardiovascular protection.Brown NJ. Eplerenone: cardiovascular protection. Circulation 2003, 107: 2512-8. PMID: 12756192, DOI: 10.1161/01.CIR.0000071081.35693.9A.
  • Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1.Sawathiparnich P, Murphey LJ, Kumar S, Vaughan DE, Brown NJ. Effect of combined AT1 receptor and aldosterone receptor antagonism on plasminogen activator inhibitor-1. The Journal Of Clinical Endocrinology And Metabolism 2003, 88: 3867-73. PMID: 12915681, DOI: 10.1210/jc.2003-030374.
  • Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives.Murphey LJ, Morrow JD, Sawathiparnich P, Williams GH, Vaughan DE, Brown NJ. Acute angiotensin II increases plasma F2-isoprostanes in salt-replete human hypertensives. Free Radical Biology & Medicine 2003, 35: 711-8. PMID: 14583335, DOI: 10.1016/s0891-5849(03)00395-2.
  • Tissue- and agonist-specific regulation of human and murine plasminogen activator inhibitor-1 promoters in transgenic mice.Eren M, Painter CA, Gleaves LA, Schoenhard JA, Atkinson JB, Brown NJ, Vaughan DE. Tissue- and agonist-specific regulation of human and murine plasminogen activator inhibitor-1 promoters in transgenic mice. Journal Of Thrombosis And Haemostasis : JTH 2003, 1: 2389-96. PMID: 14629474, DOI: 10.1046/j.1538-7836.2003.00437.x.
  • Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass.Pretorius M, Murphey LJ, McFarlane JA, Vaughan DE, Brown NJ. Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass. Circulation 2003, 108: 3079-83. PMID: 14656921, DOI: 10.1161/01.CIR.0000105765.54573.60.
  • Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women.Brown NJ, Abbas A, Byrne D, Schoenhard JA, Vaughan DE. Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women. Circulation 2002, 105: 304-9. PMID: 11804984, DOI: 10.1161/hc0302.102570.
  • Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans.Sawathiparnich P, Kumar S, Vaughan DE, Brown NJ. Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans. The Journal Of Clinical Endocrinology And Metabolism 2002, 87: 448-52. PMID: 11836266, DOI: 10.1210/jcem.87.2.7980.
  • Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema.Lefebvre J, Murphey LJ, Hartert TV, Jiao Shan R, Simmons WH, Brown NJ. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension 2002, 39: 460-4. PMID: 11882590, DOI: 10.1161/hy0202.103054.
  • Smoking impairs bradykinin-stimulated t-PA release.Pretorius M, Rosenbaum DA, Lefebvre J, Vaughan DE, Brown NJ. Smoking impairs bradykinin-stimulated t-PA release. Hypertension 2002, 39: 767-71. PMID: 11897760, DOI: 10.1161/hy0302.105767.
  • G protein-coupled receptor kinase 4 gene variants in human essential hypertension.Felder RA, Sanada H, Xu J, Yu PY, Wang Z, Watanabe H, Asico LD, Wang W, Zheng S, Yamaguchi I, Williams SM, Gainer J, Brown NJ, Hazen-Martin D, Wong LJ, Robillard JE, Carey RM, Eisner GM, Jose PA. G protein-coupled receptor kinase 4 gene variants in human essential hypertension. Proceedings Of The National Academy Of Sciences Of The United States Of America 2002, 99: 3872-7. PMID: 11904438, PMCID: PMC122616, DOI: 10.1073/pnas.062694599.
  • Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition.Kaikita K, Schoenhard JA, Painter CA, Ripley RT, Brown NJ, Fogo AB, Vaughan DE. Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition. Journal Of Molecular And Cellular Cardiology 2002, 34: 617-27. PMID: 12054849, DOI: 10.1006/jmcc.2002.2001.
  • Ethnicity affects vasodilation, but not endothelial tissue plasminogen activator release, in response to bradykinin.Rosenbaum DA, Pretorius M, Gainer JV, Byrne D, Murphey LJ, Painter CA, Vaughan DE, Brown NJ. Ethnicity affects vasodilation, but not endothelial tissue plasminogen activator release, in response to bradykinin. Arteriosclerosis, Thrombosis, And Vascular Biology 2002, 22: 1023-8. PMID: 12067915, DOI: 10.1161/01.atv.0000017704.45007.1d.
  • Aldosterone and PAI-1: implications for renal injury.Brown NJ, Vaughan DE, Fogo AB. Aldosterone and PAI-1: implications for renal injury. Journal Of Nephrology 2002, 15: 230-5. PMID: 12113592.
  • The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms.Moore JH, Smolkin ME, Lamb JM, Brown NJ, Vaughan DE. The relationship between plasma t-PA and PAI-1 levels is dependent on epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms. Clinical Genetics 2002, 62: 53-9. PMID: 12123488, DOI: 10.1034/j.1399-0004.2002.620107.x.
  • A comparison of combinatorial partitioning and linear regression for the detection of epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms on plasma PAI-1 levels.Moore JH, Lamb JM, Brown NJ, Vaughan DE. A comparison of combinatorial partitioning and linear regression for the detection of epistatic effects of the ACE I/D and PAI-1 4G/5G polymorphisms on plasma PAI-1 levels. Clinical Genetics 2002, 62: 74-9. PMID: 12123491, DOI: 10.1034/j.1399-0004.2002.620110.x.
  • PAI-1 in human hypertension: relation to hypertensive groups.Srikumar N, Brown NJ, Hopkins PN, Jeunemaitre X, Hunt SC, Vaughan DE, Williams GH. PAI-1 in human hypertension: relation to hypertensive groups. American Journal Of Hypertension 2002, 15: 683-90. PMID: 12160190, DOI: 10.1016/s0895-7061(02)02952-7.
  • The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease.Brown NJ, Vaughan DE, Fogo AB. The renin-angiotensin-aldosterone system and fibrinolysis in progressive renal disease. Seminars In Nephrology 2002, 22: 399-406. PMID: 12224047, DOI: 10.1053/snep.2002.34725.
  • Improving medication use in newly admitted home healthcare patients: a randomized controlled trial.Meredith S, Feldman P, Frey D, Giammarco L, Hall K, Arnold K, Brown NJ, Ray WA. Improving medication use in newly admitted home healthcare patients: a randomized controlled trial. Journal Of The American Geriatrics Society 2002, 50: 1484-91. PMID: 12383144, DOI: 10.1046/j.1532-5415.2002.50402.x.
  • ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.Brown NJ, Kumar S, Painter CA, Vaughan DE. ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time. Hypertension 2002, 40: 859-65. PMID: 12468570, DOI: 10.1161/01.hyp.0000040264.15961.48.
  • Antihypertensive agents and the drug therapy of hypertension.Brown, N.J., and J.A. Oates. Antihypertensive agents and the drug therapy of hypertension. In Goodman and Gillman’s The Pharmacological Basis of Therapeutics, 10th edition, eds. J.G. Hardman and L.E. Limbird, McGraw-Hill, 2001, pp. 871-900.
  • Histamine, bradykinin, and their antagonists.Roberts, J.A., and N.J. Brown. Histamine, bradykinin, and their antagonists. In Goodman and Gillman’s The Pharmacological Basis of Therapeutics,10th edition, eds. J.G. Hardman and L.E. Limbird, McGraw-Hill, 2001, pp. 645-668.
  • Interactive Effect of Ethnicity and ACE Insertion/Deletion Polymorphism on Vascular Reactivity.Gainer JV, Stein CM, Neal T, Vaughan DE, Brown NJ. Interactive Effect of Ethnicity and ACE Insertion/Deletion Polymorphism on Vascular Reactivity. Hypertension 2001, 37: 46-51. PMID: 11208755, DOI: 10.1161/01.hyp.37.1.46.
  • Preprescription genotyping: not yet ready for prime time, but getting there.Roden DM, Brown NJ. Preprescription genotyping: not yet ready for prime time, but getting there. Circulation 2001, 103: 1608-10. PMID: 11273984, DOI: 10.1161/01.cir.103.12.1608.
  • Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm.Wilsdorf T, Gainer JV, Murphey LJ, Vaughan DE, Brown NJ. Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm. Hypertension 2001, 37: 1136-40. PMID: 11304515, DOI: 10.1161/01.hyp.37.4.1136.
  • Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay.Murphey LJ, Hachey DL, Vaughan DE, Brown NJ, Morrow JD. Quantification of BK1-5, the stable bradykinin plasma metabolite in humans, by a highly accurate liquid-chromatographic tandem mass spectrometric assay. Analytical Biochemistry 2001, 292: 87-93. PMID: 11319821, DOI: 10.1006/abio.2001.5073.
  • Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen.Brown NJ, Murphey LJ, Srikuma N, Koschachuhanan N, Williams GH, Vaughan DE. Interactive effect of PAI-1 4G/5G genotype and salt intake on PAI-1 antigen. Arteriosclerosis, Thrombosis, And Vascular Biology 2001, 21: 1071-7. PMID: 11397722, DOI: 10.1161/01.atv.21.6.1071.
  • Possible medication errors in home healthcare patients.Meredith S, Feldman PH, Frey D, Hall K, Arnold K, Brown NJ, Ray WA. Possible medication errors in home healthcare patients. Journal Of The American Geriatrics Society 2001, 49: 719-24. PMID: 11454109, DOI: 10.1046/j.1532-5415.2001.49147.x.
  • Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition.Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001, 104: 839-44. PMID: 11502712, DOI: 10.1161/hc3301.092803.
  • Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans.Kim KS, Kumar S, Simmons WH, Brown NJ. Inhibition of aminopeptidase P potentiates wheal response to bradykinin in angiotensin-converting enzyme inhibitor-treated humans. The Journal Of Pharmacology And Experimental Therapeutics 2000, 292: 295-8. PMID: 10604961.
  • Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production.Brown NJ, Kim KS, Chen YQ, Blevins LS, Nadeau JH, Meranze SG, Vaughan DE. Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production. The Journal Of Clinical Endocrinology And Metabolism 2000, 85: 336-44. PMID: 10634408, DOI: 10.1210/jcem.85.1.6305.
  • Prothrombotic effects of angiotensin.Brown NJ, Vaughan DE. Prothrombotic effects of angiotensin. Advances In Internal Medicine 2000, 45: 419-29. PMID: 10635057.
  • Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite.Murphey LJ, Hachey DL, Oates JA, Morrow JD, Brown NJ. Metabolism of bradykinin In vivo in humans: identification of BK1-5 as a stable plasma peptide metabolite. The Journal Of Pharmacology And Experimental Therapeutics 2000, 294: 263-9. PMID: 10871321.
  • Human beta2-adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans.Xie HG, Stein CM, Kim RB, Gainer JV, Sofowora G, Dishy V, Brown NJ, Goree RE, Haines JL, Wood AJ. Human beta2-adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans. Clinical Pharmacology And Therapeutics 2000, 67: 670-5. PMID: 10872649, DOI: 10.1067/mcp.2000.106293.
  • Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure.Vaughan DE, Brown NJ. Effects of acute angiotensin II type 1 receptor antagonism and angiotensin converting enzyme inhibition on plasma fibrinolytic parameters in patients with heart failure. Circulation 2000, 102: E43. PMID: 10931820, DOI: 10.1161/01.cir.102.6.e43.
  • Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin.Murphey LJ, Gainer JV, Vaughan DE, Brown NJ. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. Circulation 2000, 102: 829-32. PMID: 10952948, DOI: 10.1161/01.cir.102.8.829.
  • Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney International 2000, 58: 1219-27. PMID: 10972684, DOI: 10.1046/j.1523-1755.2000.00277.x.
  • Endogenous bradykinin and the renin and pressor responses to furosemide in humans.Murphey LJ, Kumar S, Brown NJ. Endogenous bradykinin and the renin and pressor responses to furosemide in humans. The Journal Of Pharmacology And Experimental Therapeutics 2000, 295: 644-8. PMID: 11046100.
  • Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway.Brown NJ, Gainer JV, Murphey LJ, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation 2000, 102: 2190-6. PMID: 11056091, DOI: 10.1161/01.cir.102.18.2190.
  • Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans.Gainer JV, Brown NJ, Bachvarova M, Bastien L, Maltais I, Marceau F, Bachvarov DR. Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. American Journal Of Hypertension 2000, 13: 1268-73. PMID: 11130770, DOI: 10.1016/s0895-7061(00)01215-2.
  • Clinical experience over 48 years with pheochromocytoma.Goldstein RE, O'Neill JA, Holcomb GW, Morgan WM, Neblett WW, Oates JA, Brown N, Nadeau J, Smith B, Page DL, Abumrad NN, Scott HW. Clinical experience over 48 years with pheochromocytoma. Annals Of Surgery 1999, 229: 755-64; discussion 764-6. PMID: 10363888, PMCID: PMC1420821, DOI: 10.1097/00000658-199906000-00001.
  • Bradykinin stimulates tissue plasminogen activator release in human vasculature.Brown NJ, Gainer JV, Stein CM, Vaughan DE. Bradykinin stimulates tissue plasminogen activator release in human vasculature. Hypertension 1999, 33: 1431-5. PMID: 10373228, DOI: 10.1161/01.hyp.33.6.1431.
  • Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.Brown NJ, Agirbasli M, Vaughan DE. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans. Hypertension 1999, 34: 285-90. PMID: 10454455, DOI: 10.1161/01.hyp.34.2.285.
  • Alpha1A-adrenergic receptor polymorphism: association with ethnicity but not essential hypertension.Xie HG, Kim RB, Stein CM, Gainer JV, Brown NJ, Wood AJ. Alpha1A-adrenergic receptor polymorphism: association with ethnicity but not essential hypertension. Pharmacogenetics 1999, 9: 651-6. PMID: 10591546.
  • Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema.Blais C, Rouleau JL, Brown NJ, Lepage Y, Spence D, Munoz C, Friborg J, Geadah D, Gervais N, Adam A. Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology 1999, 43: 293-302. PMID: 10596866, DOI: 10.1016/s0162-3109(99)00133-2.
  • Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals.Xie HG, Stein CM, Kim RB, Xiao ZS, He N, Zhou HH, Gainer JV, Brown NJ, Haines JL, Wood AJ. Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 1999, 9: 511-6. PMID: 10780271.
  • Gender affects renal vasoconstrictor response to Ang I and Ang II.Gandhi SK, Gainer J, King D, Brown NJ. Gender affects renal vasoconstrictor response to Ang I and Ang II. Hypertension 1998, 31: 90-6. PMID: 9449397, DOI: 10.1161/01.hyp.31.1.90.
  • Angiotensin-converting enzyme inhibitors.Brown NJ, Vaughan DE. Angiotensin-converting enzyme inhibitors. Circulation 1998, 97: 1411-20. PMID: 9577953, DOI: 10.1161/01.cir.97.14.1411.
  • Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature.Stein CM, Brown N, Vaughan DE, Lang CC, Wood AJ. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. Journal Of The American College Of Cardiology 1998, 32: 117-22. PMID: 9669258, DOI: 10.1016/s0735-1097(98)00210-1.
  • ACE insertion/deletion genotype affects bradykinin metabolism.Brown NJ, Blais C, Gandhi SK, Adam A. ACE insertion/deletion genotype affects bradykinin metabolism. Journal Of Cardiovascular Pharmacology 1998, 32: 373-7. PMID: 9733349, DOI: 10.1097/00005344-199809000-00006.
  • Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. The New England Journal Of Medicine 1998, 339: 1285-92. PMID: 9791144, DOI: 10.1056/NEJM199810293391804.
  • Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1.Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998, 32: 965-71. PMID: 9856958, DOI: 10.1161/01.hyp.32.6.965.
  • A model for improving medication use in home health care patients.Brown NJ, Griffin MR, Ray WA, Meredith S, Beers MH, Marren J, Robles M, Stergachis A, Wood AJ, Avorn J. A model for improving medication use in home health care patients. Journal Of The American Pharmaceutical Association (Washington,D.C. : 1996) 1998, 38: 696-702. PMID: 9861787, DOI: 10.1016/s1086-5802(16)30390-4.
  • Plasminogen activator inhibitor type 1 in diabetes and hypertension.Litchfield, W.R., N.J. Brown, and D.E. Vaughan. Plasminogen activator inhibitor type 1 in diabetes and hypertension. Current Opinion in Endocrinology, Diabetes, and Obesity 1997, 4:233-238.
  • Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin.Brown NJ, Nadeau JH, Vaughan DE. Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thrombosis And Haemostasis 1997, 77: 522-5. PMID: 9066005.
  • Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels.Stein CM, Brown N, Carlson MG, Campbell P, Wood AJ. Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels. Clinical Pharmacology And Therapeutics 1997, 61: 662-8. PMID: 9209249, DOI: 10.1016/S0009-9236(97)90101-6.
  • Recurrent angiotensin-converting enzyme inhibitor--associated angioedema.Brown NJ, Snowden M, Griffin MR. Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA 1997, 278: 232-3. PMID: 9218671, DOI: 10.1001/jama.278.3.232.
  • Angiotensin II type I receptor polymorphism in African Americans lower frequency of the C1166 variant.Gainer JV, Hunley TE, Kon V, Nadeau JH, Muldowney JA, Brown NJ. Angiotensin II type I receptor polymorphism in African Americans lower frequency of the C1166 variant. Biochemistry And Molecular Biology International 1997, 43: 227-31. PMID: 9315301, DOI: 10.1080/15216549700204001.
  • Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clinical Pharmacology And Therapeutics 1996, 60: 8-13. PMID: 8689816, DOI: 10.1016/S0009-9236(96)90161-7.
  • Increased sensitivity to bradykinin among African Americans.Gainer JV, Nadeau JH, Ryder D, Brown NJ. Increased sensitivity to bradykinin among African Americans. The Journal Of Allergy And Clinical Immunology 1996, 98: 283-7. PMID: 8757204, DOI: 10.1016/s0091-6749(96)70151-3.
  • Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy.Hunley TE, Julian BA, Phillips JA, Summar ML, Yoshida H, Horn RG, Brown NJ, Fogo A, Ichikawa I, Kon V. Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney International 1996, 49: 571-7. PMID: 8821846, DOI: 10.1038/ki.1996.81.
  • Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin.Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J. Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. The Journal Of Pharmacology And Experimental Therapeutics 1996, 279: 703-12. PMID: 8930174.
  • Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans.Gandhi SK, Ryder DH, Brown NJ. Losartan blocks aldosterone and renal vascular responses to angiotensin II in humans. Hypertension 1996, 28: 961-6. PMID: 8952583, DOI: 10.1161/01.hyp.28.6.961.
  • Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites.Burkhart DG, Brown NJ, Griffin MR, Ray WA, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. Pharmacoepidemiology And Drug Safety 1996, 5: 149-54. PMID: 15073831, DOI: 10.1002/(SICI)1099-1557(199605)5:3<149::AID-PDS222>3.0.CO;2-I.
  • The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease.Brown NJ, Vaughan DE. The Renin-Angiotensin and fibrinolytic systems co-conspirators in the pathogenesis of ischemic cardiovascular disease. Trends In Cardiovascular Medicine 1996, 6: 239-43. PMID: 21232303, DOI: 10.1016/S1050-1738(96)00091-6.
  • Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry.Daniel VC, Minton TA, Brown NJ, Nadeau JH, Morrow JD. Simplified assay for the quantification of 2,3-dinor-6-keto-prostaglandin F1 alpha by gas chromatography-mass spectrometry. Journal Of Chromatography. B, Biomedical Applications 1994, 653: 117-22. PMID: 8205238, DOI: 10.1016/0378-4347(93)e0432-p.
  • Does race predispose to angiotensin-associated angioneurotic edema?Brown NJ, Nadeau JH. Does race predispose to angiotensin-associated angioneurotic edema? Annals Of Internal Medicine 1993, 119: 1224. PMID: 8239260, DOI: 10.7326/0003-4819-119-12-199312150-00020.
  • Caffeine attenuates the renal vascular response to angiotensin II infusion.Brown NJ, Ryder D, Nadeau J. Caffeine attenuates the renal vascular response to angiotensin II infusion. Hypertension 1993, 22: 847-52. PMID: 8244516, DOI: 10.1161/01.hyp.22.6.847.
  • Miscarriage in a patient with migraines.Brown NJ, Morgan HJ. Miscarriage in a patient with migraines. Journal Of The Tennessee Medical Association 1992, 85: 475, 477. PMID: 1434611.
  • Shortness of breath induced by standing.Davis R, Brown NJ. Shortness of breath induced by standing. Journal Of The Tennessee Medical Association 1992, 85: 376-7. PMID: 1507885.
  • Abdominal pain in a Kuwaiti woman.van Burik JA, Neuzil KM, Brown NJ, Morgan HJ. Abdominal pain in a Kuwaiti woman. Journal Of The Tennessee Medical Association 1992, 85: 112, 114. PMID: 1532842.
  • Spontaneous cholesterol emboli presenting as livedo reticularis.Brown NJ, Morgan HJ. Spontaneous cholesterol emboli presenting as livedo reticularis. Journal Of The Tennessee Medical Association 1992, 85: 64. PMID: 1552733.
  • Multinodular goiter causing airway obstruction.Brown NJ, Morgan HJ. Multinodular goiter causing airway obstruction. Journal Of The Tennessee Medical Association 1992, 85: 65-6. PMID: 1552735.
  • Disseminated histoplasmosis and AIDS.Brown NJ, Morgan HJ. Disseminated histoplasmosis and AIDS. Journal Of The Tennessee Medical Association 1992, 85: 111-2. PMID: 1560653.
  • Reiter's syndrome.Brown NJ, Morgan HJ. Reiter's syndrome. Journal Of The Tennessee Medical Association 1992, 85: 163, 165. PMID: 1564931.
  • A case of polyuria.Brown NJ. A case of polyuria. Journal Of The Tennessee Medical Association 1992, 85: 220-1. PMID: 1583893.
  • A woman with superior vena cava syndrome.Brown NJ. A woman with superior vena cava syndrome. Journal Of The Tennessee Medical Association 1992, 85: 329-30. PMID: 1625457.
  • An unusual cause of hypertension.Brown NJ. An unusual cause of hypertension. Journal Of The Tennessee Medical Association 1992, 85: 19, 21. PMID: 1734117.
  • A case of hives and hip pain following steroid injection.McCroskey DJ, Brown NJ, Morgan HJ. A case of hives and hip pain following steroid injection. Journal Of The Tennessee Medical Association 1991, 84: 494-5. PMID: 1758178.
  • A woman with massive ascites.Brown NJ. A woman with massive ascites. Journal Of The Tennessee Medical Association 1991, 84: 545-6. PMID: 1787727.
  • Chickenpox in a pregnant woman.Brown NJ. Chickenpox in a pregnant woman. Journal Of The Tennessee Medical Association 1991, 84: 546-7. PMID: 1787728.
  • A pharmacodynamic interaction between caffeine and phenylpropanolamine.Brown NJ, Ryder D, Branch RA. A pharmacodynamic interaction between caffeine and phenylpropanolamine. Clinical Pharmacology And Therapeutics 1991, 50: 363-71. PMID: 1914371, DOI: 10.1038/clpt.1991.152.
  • Case report: fatal pulmonary toxoplasmosis following chemotherapy.Brown NJ, McKenzie S, Decker MD. Case report: fatal pulmonary toxoplasmosis following chemotherapy. The American Journal Of The Medical Sciences 1991, 302: 152-4. PMID: 1928224, DOI: 10.1097/00000441-199109000-00006.
  • Caffeine potentiates the renin response to diazoxide in man. Evidence for a regulatory role of endogenous adenosine.Brown NJ, Porter J, Ryder D, Branch RA. Caffeine potentiates the renin response to diazoxide in man. Evidence for a regulatory role of endogenous adenosine. The Journal Of Pharmacology And Experimental Therapeutics 1991, 256: 56-61. PMID: 1988669.
  • Octreotide: a long-acting somatostatin analog.Brown NJ. Octreotide: a long-acting somatostatin analog. The American Journal Of The Medical Sciences 1990, 300: 267-73. PMID: 2248280, DOI: 10.1097/00000441-199010000-00011.
  • Idiopathic hypereosinophilic syndrome progressing to acute myelomonocytic leukemia with chloromas.Brown NJ, Stein RS. Idiopathic hypereosinophilic syndrome progressing to acute myelomonocytic leukemia with chloromas. Southern Medical Journal 1989, 82: 1303-5. PMID: 2678506, DOI: 10.1097/00007611-198910000-00028.
  • Glucose turnover during recovery from intensive exercise.Calles J, Cunningham JJ, Nelson L, Brown N, Nadel E, Sherwin RS, Felig P. Glucose turnover during recovery from intensive exercise. Diabetes 1983, 32: 734-8. PMID: 6347770, DOI: 10.2337/diab.32.8.734.
  • The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells.Mashayekhi M, Wanjalla CN, Warren CM, Simmons JD, Ghoshal K, Pilkinton M, Bailin SS, Gabriel CL, Pozzi A, Koethe JR, Brown NJ, Kalams SA, Luther JM. The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells. Prostaglandins & Other Lipid Mediators 2022, 158: 106604. PMID: 34922004, PMCID: PMC8742790, DOI: 10.1016/j.prostaglandins.2021.106604.
Edit Profile